There are 2789 resources available
677P - Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients: A meta-analysis of randomized clinical trials
Presenter: Ray Manneh Kopp
Session: ePoster Display
623P - Real-world treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC) patients in the US, Germany, France, China and Japan
Presenter: Peter Goebell
Session: ePoster Display
680P - Cabozantinib and axitinib after VEGF therapy in patients with aRCC: A retrospective cohort study
Presenter: Janet Brown
Session: ePoster Display
626P - Estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study
Presenter: Nobuaki Matsubara
Session: ePoster Display
682P - Real-world utilization and outcomes of immune-based combination therapies or tyrosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (aRCC)
Presenter: Daniel Geynisman
Session: ePoster Display
683P - Impact of renin-angiotensin system inhibitors (RASi) on outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI)
Presenter: Pier Vitale Nuzzo
Session: ePoster Display
684P - Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma
Presenter: Eduard Roussel
Session: ePoster Display
685P - Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma
Presenter: Meta Diekstra
Session: ePoster Display
686P - Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial
Presenter: Laetitia Mauge
Session: ePoster Display